Alessandra Cesano, M.D., Ph.D. was appointed as a director of Puma Biotechnology, effective July 29, 2022. Dr. Cesano has been the Chief Medical Officer of ESSA Pharmaceuticals, a pharmaceutical company developing therapies for the treatment of prostate cancer, since July 2019.
From July 2015 until June 2019 Dr. Cesano was the Chief Medical Officer of NanoString Inc., a biotechnology company that develops translational research tools, where she focused on the development of translational and diagnostic multi-plexed assays for the characterization and measurement of mechanisms of immune response/resistance. Prior to NanoString, Dr. Cesano was Chief Medical Officer at Cleave Biosciences, Inc., a biopharmaceutical company focusing on protein therapies for the treatment of cancer and neurodegenerative diseases, and before that she served as Chief Medical Officer and Chief Operations Officer at Nodality, Inc., where she built and led the Research & Development group, while providing the overall clinical vision for the organization. Between 1998 and 2008, Dr. Cesano held various management positions at Amgen Inc., Biogen Inc. (formerly Biogen Idec) and SmithKline Beecham Pharmaceuticals, where she helped to advance various oncology drugs through late stage development and FDA approvals.
Early in her professional career, she spent 12 years conducting research in tumor immunology, including nine years at the Wistar Institute, an NCI Basic Cancer Center connected with the University of Pennsylvania.
Dr. Cesano also holds membership in several professional and scientific societies including ASCO, ESMO, ASH, EHA, AACR and the Society of Immunotherapy of Cancer ("SITC"). In the latter she has served as co-chair in the SITC Industry Committee and of the SITC Biomarker Working Group, and she currently serves as Associate Editor for the Biomarker section of the Journal for ImmunoTherapy of Cancer, co-chair of the Regulatory Committee, and as the elected At-Large Director of the SITC for the 2020-2023 term. Over her career, she has been an author on over 130 publications.
Dr. Cesano received an M.D. summa cum laude, a Board Certification in Oncology and a Ph.D. in Tumor Immunology from the University of Turin. Dr. Cesano was selected as a director because of her extensive background in biotechnology research and development and her experience in the life sciences industry.
What is Alessandra Cesano's net worth?
The estimated net worth of Alessandra Cesano is at least $315.55 thousand as of July 18th, 2025. Cesano owns 41,850 shares of Puma Biotechnology stock worth more than $315,549 as of April 28th. This net worth evaluation does not reflect any other investments that Cesano may own. Learn More about Alessandra Cesano's net worth.
How do I contact Alessandra Cesano?
Has Alessandra Cesano been buying or selling shares of Puma Biotechnology?
Alessandra Cesano has not been actively trading shares of Puma Biotechnology during the last ninety days. Most recently, Alessandra Cesano sold 27,000 shares of the business's stock in a transaction on Friday, July 18th. The shares were sold at an average price of $3.37, for a transaction totalling $90,990.00. Following the completion of the sale, the director now directly owns 41,850 shares of the company's stock, valued at $141,034.50. Learn More on Alessandra Cesano's trading history.
Who are Puma Biotechnology's active insiders?
Puma Biotechnology's insider roster includes Alan Auerbach (CEO), Alessandra Cesano (Director), Allison Dorval (Director), Douglas Hunt (Insider), Jeffrey Ludwig (Insider), Ann Miller (Director), Jay Moyes (Director), Maximo Nougues (CFO), Adrian Senderowicz (Director), Brian Stuglik (Director), and Alvin Wong (Insider). Learn More on Puma Biotechnology's active insiders.
Are insiders buying or selling shares of Puma Biotechnology?
During the last year, insiders at the biopharmaceutical company sold shares 16 times. They sold a total of 237,586 shares worth more than $951,627.52. The most recent insider tranaction occured on January, 7th when CEO Alan H Auerbach sold 18,012 shares worth more than $105,910.56. Insiders at Puma Biotechnology own 23.3% of the company.
Learn More about insider trades at Puma Biotechnology. Information on this page was last updated on 1/7/2026.
